Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Human-Spongiosa vs collacone for alveolar ridge volume stability
NCT03089619Phase 4Terminated
- Sponsor
- Universitätsklinikum Greifswald
- Start
- May 2016
- Primary completion
- Jan 2022
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Human-Spongiosa in Alveolar bone loss and Bone resorption (2 arms), sponsored by Universitätsklinikum Greifswald. Primary endpoint: Extent of bone resorption at 13.5 months. Started May 2016; status: terminated.
02
Drugs
Human-Spongiosa
03
Conditions
Alveolar bone lossBone resorption
Beyond the preview
Go deeper on NCT03089619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03089619.